Kirenol: A Potential Natural Lead Molecule for a New Drug Design, Development, and Therapy for Inflammation

Naurah, Nabihah Nasir and Mahendran, Sekar and Fuloria, Shivkanya and Gan, Siew Hua and Nur Najihah, Izzati Mat Rani and Ravi, Subban and Begum, M Yasmin and Chidambaram, Kumarappan and Kathiresan, V Sathasivam and Jeyabalan, Srikanth and Dhiravidamani, Arulmozhi and Thangavelu, Lakshmi and Lum, Pei Teng and Vetriselvan, Subramaniyan and Wu, Yuan Seng * and Abdul Kalam, Azad and Fuloria, Neeraj Kumar (2022) Kirenol: A Potential Natural Lead Molecule for a New Drug Design, Development, and Therapy for Inflammation. Molecules, 27 (3). ISSN 1420-3049

[img]
Preview
Text
Wu Yuan Seng_Kirenol a potential natural lead molecule for a new drug desgin.pdf - Published Version
Available under License Creative Commons Attribution.

Download (4MB) | Preview
Official URL: https://doi.org/10.3390/molecules27030734

Abstract

Kirenol, a potential natural diterpenoid molecule, is mainly found in Sigesbeckia species. Kirenol has received a lot of interest in recent years due to its wide range of pharmacological actions. In particular, it has a significant ability to interact with a wide range of molecular targets associated with inflammation. In this review, we summarise the efficacy and safety of kirenol in reducing inflammation, as well as its potential mechanisms of action and opportunities in future drug development. Based on the preclinical studies reported earlier, kirenol has a good therapeutic potential against inflammation involved in multiple sclerosis, inflammatory bowel disorders, diabetic wounds, arthritis, cardiovascular disease, bone damage, and joint disorders. We also address the physicochemical and drug-like features of kirenol, as well as the structurally modified kirenol-derived molecules. The inhibition of pro-inflammatory cytokines, reduction in the nuclear factor kappa-B (NF-κB), attenuation of antioxidant enzymes, stimulation of heme-oxygenase-1 (HO-1) expression, and nuclear factor erythroid 2-related factor 2 (Nrf2) phosphorylation are among the molecular mechanisms contributing to kirenol’s anti-inflammatory actions. Furthermore, this review also highlights the challenges and opportunities to improve the drug delivery of kirenol for treating inflammation. According to the findings of this review, kirenol is an active molecule against inflammation in numerous preclinical models, indicating a path to using it for new drug discovery and development in the treatment of a wide range of inflammations.

Item Type: Article
Uncontrolled Keywords: kirenol; inflammation; anti-inflammatory; molecular mechanism; drug development; molecular docking
Subjects: Q Science > QK Botany
R Medicine > RB Pathology
R Medicine > RM Therapeutics. Pharmacology
Divisions: Others > Non Sunway Academics
Sunway University > School of Medical and Life Sciences [formerly School of Healthcare and Medical Sciences until 2020] > Sunway Microbiome Centre [formerly Centre for Virus and Vaccine Research until 2023]
Depositing User: Ms Yong Yee Chan
Related URLs:
Date Deposited: 06 Aug 2024 07:10
Last Modified: 06 Aug 2024 07:10
URI: http://eprints.sunway.edu.my/id/eprint/3020

Actions (login required)

View Item View Item